AFFY Affymax Inc.
- 2.25 P/E
- 131.22 P/S
- 1.07 P/B
- 0.082 EPS
- 0.05 / 0% Dividend
- 42,824.00 Avg. Vol.
- 37.45M Shares
- 6.7M Market Cap.
Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
MicroCap Daily - Nov 3, 2014
Business Wire (press release) - Nov 26, 2014
HotStocked - Jun 17, 2014
GlobeNewswire (press release) - Jul 18, 2013
iStockAnalyst (press release) - Feb 25, 2013
Affymax Shares Plunge on Drug's Recall - Wall Street Journal
HotStocked - Sep 20, 2013
Insider Monkey (blog) - Apr 8, 2013
Insider Monkey (blog) - Jun 10, 2013
HotStocked - Aug 30, 2013
GlobeNewswire (press release) - Mar 4, 2013